Medicine guide

TECARTUS

As listed in the register: TECARTUS 0,4 - 2 x 10e8 CELULAS DISPERSION PARA PERFUSION

0,4 - 2 x 10e8 células inyectable 68 ml · dispersion para perfusion

  • Prescription only
  • Cancer treatments and immune-system medicines
Made by
Kite Pharma Eu B.V.

Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.

What it is for

Medicine groupCancer treatments and immune-system medicinesL01XL06

Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet

Same active substance, strength and form in other countries

Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.

Medicine passport: one printable page to show a pharmacist abroad

CanadaNo exact match for this strength and form

NetherlandsNo exact match for this strength and form

SwitzerlandNo exact match for this strength and form

Details

Made byKite Pharma Eu B.V.
Active substanceBrexucabtagén autoleucel
Used inCancer treatments and immune-system medicines
Strength0,4 - 2 x 10e8 células inyectable 68 ml
Formdispersion para perfusion
ClassificationL01XL06 · Cancer treatments and immune-system medicines
Routevía intravenosa
MarketedYes, according to the register
Orphan medicineYes — designated for a rare disease, according to the register
Additional monitoring ▼Yes — under additional monitoring (black triangle). Report suspected side effects.
DrivingThe regulator flags that this medicine can affect the ability to drive.
Name in the registerTECARTUS 0,4 - 2 x 10e8 CELULAS DISPERSION PARA PERFUSION
Nº Registro1201492001

Source: CIMA — Centro de Información online de Medicamentos · 2026-09-30 · not reviewed by a clinician

Fuente: Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), CIMA. Reuse terms: Aviso legal AEMPS.